Clinical Trial Search

Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Event Rate for a Cardiovascular Composite of Incident Myocardial Infarction, Stroke, or Heart Failure — 10.62; 8.13 Events per 1000 person years

Primary: Osteoclast Differentiation Ex-vivo — 8; 12; 11; 5 OC/mm2

Primary: Disease Activity — 3.38; 3.62 score on a scale

Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04

Primary: Change in VO2 Max, Maximum Oxygen Uptake in ml/Min/kg is the Standard Index of Cardio-respiratory Fitness — 3.82; -0.44 ml/min/kg — p=0.002

Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale

Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01

Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3

Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…

Primary: Number of Subjects With Lipids Checked (Available Now Through National Laboratory Chain) or That Reported Having Their Lipids Checked by Their 1-week or 3-month Visit…

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants

Primary: Hospital Anxiety and Depression Scale (HADS) — 107; 46; 20; 27 participants

Primary: Number of Participants Diagnosed With Rheumatoid Arthritis Also Found to Have Dry Eye Disease — 275 participants

Primary: Change in Tissue Sodium — 17.1; 16.7 mmol/L — p=0.55

Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants

Primary: Change From Baseline in Joint Status Assessed by Radiographic (Roentgen) Progression — 6.9; 24.3; 0.0; 0.3 scores on a scale

Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects

Primary: Evaluation of Disease Duration: Time From Diagnosis to Disease-Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis — 11.7177 Months

Primary: Slow Wave Sleep — 82.6; 67.3 Minutes

Primary: Low Synovitis Scores — 1 Participants

Primary: DAS28-ESR — 3.75; 3.72; 3.59; 3.69 units on a scale — p=0.82

Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055

Primary: Incidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi — 426.8; 471.9…

Primary: Prevalence of Vitamin B12 Deficiency — 3; 6; 4 participants

Primary: Brachial Artery Diameter Change From Baseline in Response to Reactive Hyperemia — 8.3; 9.43 % changes in diameter of artery

Primary: Number of Participants With Level of Education Completed — 01; 15; 86; 59 Participants